surmount-1 trial tirzepatide non-diabetic weight loss once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 SURPASS to SURMOUNT: The Tirzepatide

Upregulation of melanin biosynthesis or increase in the number either of normal or of atypical oral mucosal melanocytes may bring about oral mucosal melanin hyperpigmentation

3.Co-administration with Absorption Enhancers Certain formulations incorporate permeation enhancers-such as DMSO (dimethyl sulfoxide)-to boost absorption rates

This is where the majority of results happen

2015;4:CD011076

"That might be seen as being kind of selfish, because those people quite understandably want to lose some weight, but the drug is not tested or designed to help people in that position." He says mixing and injecting weight loss drugs at home comes with "huge risks"